ERBB2 and breast carcinoma: On 5 August 2022, the ADC drug fam-trastuzumab deruxtecan-nxki (Enhertu) received FDA approval for unresectable or metastatic HER2-low breast cancer patients who have received prior chemotherapy for metastatic disease or who developed disease recurrence during or within six months of completing adjuvant therapy [48].